BCLI - Brainstorm Cell Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.98
+0.02 (+0.51%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.96
Open4.00
Bid3.98 x 1000
Ask4.30 x 1800
Day's Range3.96 - 4.03
52 Week Range2.88 - 5.35
Volume30,796
Avg. Volume69,242
Market Cap82.265M
Beta2.60
PE Ratio (TTM)N/A
EPS (TTM)-0.39
Earnings DateOct 15, 2018 - Oct 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn®

    NEW YORK and PETACH TIKVAH, Israel, Sept. 13, 2018-- BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United ...

  • GlobeNewswire9 days ago

    BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform

    NEW YORK and PETACH TIKVAH, Israel, Sept. 12, 2018-- BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today ...

  • GlobeNewswire16 days ago

    BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference

    NEW YORK and PETACH TIKVAH, Israel, Sept. 05, 2018-- BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company ...

  • GlobeNewswire17 days ago

    BrainStorm Appoints Arturo Araya as Chief Commercial Officer

    NEW YORK and PETACH TIKVAH, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that is has appointed Arturo O. Araya, M.A., M.B.A., as Chief Commercial Officer, effective immediately. Mr. Araya brings to the BrainStorm team nearly two decades of global pharmaceutical commercialization, marketing, and general management experience, including as Global Head of Commercial of Novartis' Cell and Gene Therapies Unit.

  • GlobeNewswire23 days ago

    BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference

    NEW YORK and PETACH TIKVAH, Israel, Aug. 29, 2018-- BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company ...

  • Zacks Small Cap Research29 days ago

    BCLI: Positive Interim Safety Analysis for Phase 3 Trial…

    There were no significant safety issues and the DSMB recommended that the trial continue as planned. This is an important milestone for the company as it is the first trial to use repeated injections of NurOwn®, thus it is reassuring to see that there have been no safety issues thus far with repeated injections.

  • GlobeNewswire29 days ago

    BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALS

    NEW YORK, and PETACH TIKVA, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed the pre-specified interim analysis of safety outcomes for the first 31 participants treated with NurOwn® in the Phase 3 trial in ALS (NCT03280056). The DSMB indicated there were no significant safety concerns and recommended that the trial continue, as planned. BrainStorm is conducting a repeat dose US Phase 3 trial of NurOwn® for ALS participants at 6 US sites, supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989).

  • PR Newswire2 months ago

    BrainStorm Announces Grant of a New European Patent for NurOwn®

    NEW YORK and PETACH TIKVAH, Israel, July  25, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, ...

  • Zacks Small Cap Research2 months ago

    BCLI: Phase 3 Trial in ALS Fully Funded; Company to Announced Additional Indications for NurOwn

    On July 23, 2018, BrainStorm Cell Therapeutics, Inc. (BCLI) announced financial results for the second quarter of 2018 and provided a business update. As expected, the company did not report any revenues for the quarter. The company recorded R&D expenses for the second quarter of 2017 and 2018 net of research and development grants from the Israel Innovation Authority (IIA, formerly the Office of the Chief Scientist) and the California Institute for Regenerative Medicine (CIRM).

  • PR Newswire2 months ago

    BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update

    Conference Call and Webcast at 8.30am ET Today NEW YORK and PETACH TIKVAH, Israel , July 23, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell ...

  • ACCESSWIRE2 months ago

    Brainstorm Cell Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 23, 2018 at 8:30 AM ...

  • PR Newswire2 months ago

    BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23

    Conference Call and Live Webcast at 8.30am ET NEW YORK and PETACH TIKVAH, Israel , July 17, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell ...

  • Zacks Small Cap Research3 months ago

    BCLI: Additional Manufacturing Facility Secured for Phase 3 ALS Trial

    On July 2, 2018, BrainStorm Cell Therapeutics, Inc. (BCLI) announced that the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute will serve as a second manufacturing facility to supply NurOwn® for the company’s ongoing Phase 3 clinical trial in amyotrophic lateral sclerosis (ALS). Dana Farber was previously used as a manufacturing facility of NurOwn® in the Phase 2 trial.

  • PR Newswire3 months ago

    BrainStorm Granted Japanese Patent for NurOwn®

    NEW YORK and PETACH TIKVAH, Israel, July 5, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today ...

  • MarketWatch3 months ago

    Meet the one patient who will get access to this experimental ALS therapy before it’s approved

    A biotechnology company had planned to make its experimental therapy for the deadly neuromuscular disease amyotrophic lateral sclerosis, or ALS, which has no cure, available to patients under a new “right to try” law championed by President Donald Trump. Brainstorm Cell Therapeutics Inc.’s (BCLI) stem cell-based treatment, which is personalized to the individual, would have an estimated price tag of more than $300,000 per patient, Chief Executive Chaim Lebovits told Bloomberg last week.

  • PR Newswire3 months ago

    BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production

    NEW YORK, PETACH TIKVA, Israel and BOSTON, July 2, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has contracted with the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute (Dana-Farber) as a second U.S. manufacturing site to supply NurOwn® for the company's ongoing randomized, double-blind, multi-dose Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS) as well as other potential indications. "We are pleased to announce a second partnership with Dana-Farber for the manufacturing of NurOwn," said Chaim Lebovits, president and CEO of BrainStorm.

  • PR Newswire3 months ago

    BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello

    Susan Ward, Ph.D. (Pfizer) Appointed Head of Clinical Operations Joe Petroziello (Juno Therapeutics) Appointed VP of Scientific & Corporate Communications NEW YORK and PETACH TIKVAH, Israel, June 28, 2018 ...

  • PR Newswire3 months ago

    BrainStorm Provides Update on "Right to Try" Policy

    NEW YORK and PETACH TIKVA, Israel, June 26, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that after careful evaluation of the newly enacted "Right to Try" (RTT) Act, it will not make NurOwn® available under this legislation at this time. The company will continue to focus efforts on completing the ongoing NurOwn® Phase 3 study as quickly as possible with the goal of bringing a meaningful treatment option to amyotrophic lateral sclerosis (ALS) patients. Brainstorm has carefully evaluated the ethical, legal and practical aspects of the newly enacted RTT legislation in detail, and has received detailed feedback from patients, clinicians, regulatory and legal experts.

  • PR Newswire3 months ago

    BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy

    Conference Call and Live Webcast at 8:30am Eastern Time NEW YORK and PETACH TIKVAH, Israel , June 25, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ...

  • The ‘Right to Try’ Could Cost Dying Patients a Fortune
    Bloomberg3 months ago

    The ‘Right to Try’ Could Cost Dying Patients a Fortune

    A small biotechnology company may be the first to offer dying patients unproven drugs under a new U.S. law called Right to Try that deregulated access to such experimental treatments. While details are still being worked out, the company’s chief executive officer pointed to the price of bespoke cell therapies used to treat cancer that cost more than $300,000. “Companies cannot be NGOs,” the nongovernmental organizations that help provide care to impoverished countries, Brainstorm CEO Chaim Lebovits said in a phone interview.

  • Zacks Small Cap Research3 months ago

    BCLI: Determining Path Forward Following “Right to Try”; Warrant Exercise Raises $12.3M

    On June 7, 2018, BrainStorm Cell Therapeutics (BCLI) held a conference call to engage with ALS patients and caregivers following the signing of the “Right-to-Try” legislation by President Trump. The law allows those with a terminal illness to seek out treatments from pharmaceutical companies that have not yet been approved by the FDA. Before the passage of the “Right-to-Try” law, patients could petition the FDA for access to an experimental treatment through the “expanded access program”.

  • PR Newswire3 months ago

    BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share

    NEW YORK and PETACH TIKVA, Israel , June 7, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today ...

  • Should You Worry About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) CEO Pay?
    Simply Wall St.4 months ago

    Should You Worry About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) CEO Pay?

    Chaim Lebovits is the CEO of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI), which has recently grown to a market capitalization of US$91.73M. Recognizing whether CEO incentives are aligned with shareholders isRead More...

  • PR Newswire4 months ago

    BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing

    Conference call and live webcast on June 7th at 8:15am EDT NEW YORK and PETACH TIKVAH, Israel, June 1, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ...